Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Nifedipine Market by Product (Nifedipine Controlled Release Tablets, Nifedipine Extended Action Tablets) and by Application (Primary Pulmonary Hypertension, Heart Failure, Raynauds Syndrome, Cephalagra, Bronchial Asthma, Premature Labor): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03658

Pages: NA

Charts: NA

Tables: NA

Nifedipine is a drug that belongs to the class of calcium channel blocker, which interrupts the movement of calcium in the walls of the arteries. Nifedipine is used specifically to treat hypertension, arrhythmias, and angina. In addition, it has several other therapeutical applications such as ryanoids syndrome, cephalagra, and others.

Factors such as increase in geriatric population, healthcare expenditure, incidence of chronic diseases such as heart failure, arrhythmias, & hypertension, and healthcare awareness fuel the growth of the market. However, stringent government regulations and side-effects of the drugs such as hypotension, gastric ulcers, and congestive heart failure hinder the market growth. Ongoing R&D activities are anticipated to present new growth opportunities.

The market is segmented on the basis of product, application, and region. By product, the market is bifurcated into nifedipine controlled release tablets and nifedipine extended release tablets. Based on application, the market is categorized into primary pulmonary hypertension, heart failure, ryanoids disease, cephalagra, bronchial asthma, and premature labor. By region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The study provides an in-depth analysis of the nifedipine market, with current trends and future estimations to elucidate investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
  • The report provides a quantitative analysis to help stakeholders to capitalize on prevailing market opportunities in terms of value.
  • Extensive analysis of different segments helps understand various products of the market.
  • Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.

 Key Market Segments

  • By Product
    • Nifedipine Controlled Release Tablets
    • Nifedipine Extended Action Tablets
  • By Application
    • Primary Pulmonary Hypertension
    • Heart Failure
    • Raynauds Syndrome
    • Cephalagra
    • Bronchial Asthma
    • Premature Labor
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Vectura Group plc
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Abbott Laboratories
  • Boehringer Ingelheim GmbH
  • Pfizer Inc.
  • Merck and Co., Inc.
  • Novartis AG
  • F. Hoffmann La Roche AG
  • Teva Pharmaceutical Industries Ltd.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: NIFEDIPINE MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Nifedipine Controlled Release Tablets

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Nifedipine Extended Action Tablets

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: NIFEDIPINE MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Primary Pulmonary Hypertension

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Heart Failure

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Raynauds Syndrome

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Cephalagra

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Bronchial Asthma

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Premature Labor

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

  • CHAPTER 6: NIFEDIPINE MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Nifedipine Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Nifedipine Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Nifedipine Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Nifedipine Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Nifedipine Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Nifedipine Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Nifedipine Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Nifedipine Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Nifedipine Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Nifedipine Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Nifedipine Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Nifedipine Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Nifedipine Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Nifedipine Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Nifedipine Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Nifedipine Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Nifedipine Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Nifedipine Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Nifedipine Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Nifedipine Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Nifedipine Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Nifedipine Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Nifedipine Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Nifedipine Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Nifedipine Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. GlaxoSmithKline Plc

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Novartis AG

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Merck And Co., Inc.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Abbott Laboratories

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Boehringer Ingelheim GmbH

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. AstraZeneca Plc

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. F. Hoffmann La Roche AG

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Teva Pharmaceutical Industries Ltd.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Vectura Group Plc

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Pfizer Inc.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NIFEDIPINE MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL NIFEDIPINE MARKET FOR NIFEDIPINE CONTROLLED RELEASE TABLETS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL NIFEDIPINE MARKET FOR NIFEDIPINE EXTENDED ACTION TABLETS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL NIFEDIPINE MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL NIFEDIPINE MARKET FOR PRIMARY PULMONARY HYPERTENSION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL NIFEDIPINE MARKET FOR HEART FAILURE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL NIFEDIPINE MARKET FOR RAYNAUDS SYNDROME, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL NIFEDIPINE MARKET FOR CEPHALAGRA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL NIFEDIPINE MARKET FOR BRONCHIAL ASTHMA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL NIFEDIPINE MARKET FOR PREMATURE LABOR, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL NIFEDIPINE MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA NIFEDIPINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 15. U.S. NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 16. U.S. NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 17. CANADA NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 18. CANADA NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 20. MEXICO NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE NIFEDIPINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 25. FRANCE NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 27. GERMANY NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 28. ITALY NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 29. ITALY NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 31. SPAIN NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 32. UK NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 33. UK NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 35. RUSSIA NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 37. REST OF EUROPE NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC NIFEDIPINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 41. CHINA NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 42. CHINA NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 44. JAPAN NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 45. INDIA NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 46. INDIA NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 48. SOUTH KOREA NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 50. AUSTRALIA NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 52. THAILAND NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 54. MALAYSIA NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 56. INDONESIA NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA NIFEDIPINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 63. BRAZIL NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH AFRICA NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 67. SAUDI ARABIA NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 68. UAE NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 69. UAE NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 71. ARGENTINA NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA NIFEDIPINE, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 73. REST OF LAMEA NIFEDIPINE, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 74. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 75. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 76. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 77. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 78. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 80. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 81. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 82. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 83. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 85. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 86. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 87. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 88. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 90. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 91. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 92. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 93. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. BOEHRINGER INGELHEIM GMBH: KEY EXECUTIVES
  • TABLE 95. BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
  • TABLE 96. BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
  • TABLE 97. BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
  • TABLE 98. BOEHRINGER INGELHEIM GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 100. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 101. ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 102. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 103. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. F. HOFFMANN LA ROCHE AG: KEY EXECUTIVES
  • TABLE 105. F. HOFFMANN LA ROCHE AG: COMPANY SNAPSHOT
  • TABLE 106. F. HOFFMANN LA ROCHE AG: OPERATING SEGMENTS
  • TABLE 107. F. HOFFMANN LA ROCHE AG: PRODUCT PORTFOLIO
  • TABLE 108. F. HOFFMANN LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 110. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 111. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 112. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 113. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. VECTURA GROUP PLC: KEY EXECUTIVES
  • TABLE 115. VECTURA GROUP PLC: COMPANY SNAPSHOT
  • TABLE 116. VECTURA GROUP PLC: OPERATING SEGMENTS
  • TABLE 117. VECTURA GROUP PLC: PRODUCT PORTFOLIO
  • TABLE 118. VECTURA GROUP PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. PFIZER INC.: KEY EXECUTIVES
  • TABLE 120. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 121. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 122. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 123. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL NIFEDIPINE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL NIFEDIPINE MARKET
  • FIGURE 3. SEGMENTATION NIFEDIPINE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN NIFEDIPINE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNIFEDIPINE MARKET
  • FIGURE 11. NIFEDIPINE MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. NIFEDIPINE MARKET FOR NIFEDIPINE CONTROLLED RELEASE TABLETS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. NIFEDIPINE MARKET FOR NIFEDIPINE EXTENDED ACTION TABLETS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. NIFEDIPINE MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. NIFEDIPINE MARKET FOR PRIMARY PULMONARY HYPERTENSION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. NIFEDIPINE MARKET FOR HEART FAILURE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. NIFEDIPINE MARKET FOR RAYNAUDS SYNDROME, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. NIFEDIPINE MARKET FOR CEPHALAGRA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. NIFEDIPINE MARKET FOR BRONCHIAL ASTHMA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. NIFEDIPINE MARKET FOR PREMATURE LABOR, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: NIFEDIPINE MARKET
  • FIGURE 27. TOP PLAYER POSITIONING, 2024
  • FIGURE 28. GLAXOSMITHKLINE PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. MERCK AND CO., INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. BOEHRINGER INGELHEIM GMBH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. BOEHRINGER INGELHEIM GMBH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. BOEHRINGER INGELHEIM GMBH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. ASTRAZENECA PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. F. HOFFMANN LA ROCHE AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. F. HOFFMANN LA ROCHE AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. F. HOFFMANN LA ROCHE AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. VECTURA GROUP PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. VECTURA GROUP PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. VECTURA GROUP PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Nifedipine Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved